Testicular Cancer Stages Explained
Testicular cancer stage combines the pathology from orchidectomy, CT findings and post-orchidectomy tumour markers. Stage I means there is no radiological spread beyond the testicle; stage II usually means spread to retroperitoneal lymph nodes; stage III includes more advanced nodal or distant metastatic disease. Testicular cancer staging is unusual because serum marker levels (the “S” category) are part of the system. Stage is then combined with histology—seminoma or non-seminoma—and, for metastatic disease, the IGCCCG prognostic group to choose treatment.
Testicular Cancer Stages at a glance
| Stage | General meaning | Examples |
|---|---|---|
| I | Cancer confined to testis after orchidectomy; no radiological metastasis | Stage IA/IB; IS used when markers remain elevated |
| II | Spread to retroperitoneal lymph nodes | IIA, IIB, IIC by nodal size/extent |
| III | More extensive nodal/distant disease | Lung or other distant metastases; S category contributes |
The TNM-S components
- T: local extent of tumour in the testicle/spermatic cord/scrotum, determined mainly by pathology
- N: retroperitoneal regional lymph-node involvement
- M: distant metastasis
- S: post-orchidectomy serum AFP, beta-hCG and LDH category
Stage I
Imaging shows no metastatic disease. Stage IA/IB subdivision reflects local pathological features. Stage IS is different: imaging may look clear, but markers fail to normalise appropriately, suggesting persistent disease and usually requiring systemic treatment.
Stage II
Cancer has spread to regional retroperitoneal nodes. Treatment differs between seminoma and non-seminoma and depends on node size and marker status. Marker-positive non-seminoma is generally treated according to metastatic germ-cell tumour protocols.
Stage III and prognostic groups
Stage III includes non-regional nodal or visceral metastases and/or particular marker patterns. For metastatic germ-cell cancer, IGCCCG classification separates good, intermediate and poor prognosis based on histology, primary site, metastatic sites and marker levels. It guides chemotherapy intensity and counselling.
Why markers must be repeated after surgery
AFP and beta-hCG should decline according to expected half-lives. A persistent or rising level can change the stage even if the CT does not show visible disease. Serial trends are therefore essential.
Stage IS is easy to misunderstand
Stage IS means imaging may show no metastasis, but tumour markers remain persistently elevated or fail to fall appropriately after orchidectomy. This indicates likely microscopic systemic disease and is not managed like ordinary stage I surveillance.
Stage and IGCCCG prognosis answer different questions
TNM-S stage describes extent of disease. In metastatic germ-cell cancer, the IGCCCG group uses primary site, metastatic sites and marker levels to classify good, intermediate or poor prognosis and guide chemotherapy. A patient can therefore need both labels.
High stage does not mean the same prognosis as in most solid tumours
Metastatic testicular germ-cell cancer remains highly curable, particularly in good-risk disease. Patients should avoid importing survival expectations from unrelated stage III or IV cancers; treatment sensitivity and tumour biology are very different.
Testicular staging is unusually dependent on tumour markers
Stage is based on the primary tumour, retroperitoneal/distant spread and the post-orchidectomy serum marker category. A patient can therefore have small-volume imaging disease but a higher-risk systemic category because markers remain markedly elevated. Seminoma and non-seminoma are also staged and risk-stratified differently for metastatic treatment. Ask for the post-orchidectomy marker trend, not only the pre-operative value.
When to seek earlier medical review
Marker values that rise or fail to fall after orchidectomy should be reviewed promptly because they can affect stage and treatment. New neurological symptoms, severe breathlessness or uncontrolled pain in known metastatic disease warrants urgent assessment.
Emergency warning signs
- Sudden severe testicular pain, especially with nausea (torsion must be excluded urgently)
- Rapidly increasing scrotal swelling or severe pain
- Breathing difficulty, severe headache or neurological symptoms in a patient with known advanced cancer
- Fever or worsening wound redness after surgery
What to bring to your consultation
- Orchidectomy HPE
- Pre- and post-orchidectomy AFP/beta-hCG/LDH
- CT staging scans
- Any chemotherapy/radiotherapy records
Questions to ask your doctor
- Is this stage based on post-orchidectomy markers?
- Do I also need an IGCCCG prognostic group?
- What aspect of the stage determines the chemotherapy regimen?
FAQs
Is stage II testicular cancer still curable?
Yes. Stage II and many stage III germ-cell cancers remain highly curable with appropriate treatment.
What is stage IS?
It refers to persistent elevation of tumour markers after orchidectomy without radiological metastasis, indicating likely microscopic disease.
Does a large testicular tumour automatically mean advanced stage?
No. A large primary tumour can still be stage I if there is no metastatic disease and post-operative markers behave appropriately.
Is IGCCCG the same as TNM stage?
No. IGCCCG is a prognostic classification used mainly for metastatic germ-cell cancer and complements stage.
Related reading
- Testicular Cancer: Symptoms and Treatment
- Painless Testicular Lump: When to Worry
- Tumor Markers AFP, Beta-hCG and LDH Explained
- Radical Orchidectomy Explained
- Testicular Cancer and Fertility
- Kidney Cancer Stage Explained
- Chemotherapy for Testicular Cancer
- Surveillance After Testicular Cancer Treatment
- Urologist in Latur
References
- European Association of Urology (EAU). Testicular Cancer Guidelines, 2026. Diagnostic Evaluation https://uroweb.org/guidelines/testicular-cancer/chapter/diagnostic-evaluation
- European Association of Urology (EAU). Testicular Cancer Guidelines, 2026. Disease Management https://uroweb.org/guidelines/testicular-cancer/chapter/disease-management
- European Association of Urology (EAU). Testicular Cancer Guidelines, 2026. Follow-up After Curative Therapy https://uroweb.org/guidelines/testicular-cancer/chapter/followup-after-curative-therapy
- National Cancer Institute. Testicular Cancer Treatment (PDQ) – Patient Version https://www.cancer.gov/types/testicular/patient/testicular-treatment-pdq